Gilead Sciences, Inc. (NASDAQ: GILD) today announced positive topline results from the Phase 3 ARTISTRY-1 trial. The ...

The ARTISTRY-1 Phase III trial demonstrated that a single-tablet regimen of bictegravir 75 mg/lenacapavir 50 mg maintains viral suppression and simplifies therapy for people living with HIV, ...

Topline results were announced from a phase 3 trial evaluating bictegravir 75mg/lenacapavir 50mg (BIC/LEN), an investigational single-tablet regimen for the treatment of HIV-1.

Gilead Sciences has developed an industry-leading HIV portfolio in recent years with its megablockbuster daily treatment ...

Gilead (GILD) stock gains as the company's new single-tablet HIV regimen is proven as effective as multi-tablet therapies in ...

Gilead's Phase 3 ARTISTRY-1 trial shows its single-tablet HIV regimen of bictegravir and lenacapavir matches the efficacy and safety of current therapy.

Investing.com -- Gilead Sciences Inc (NASDAQ:GILD) stock rose 2.7% on Thursday after the company announced positive topline ...

The trial evaluated treatment responses in patients who were virologically suppressed, switching from a multi-tablet regimen ...

The battle against HIV in sub-Saharan Africa has always been as much about systems and science as about the virus itself. Antiretroviral therapy has turned what was once a death sentence into a ...

Gilead (GILD) announced topline results from the Phase 3 ARTISTRY-1 trial. The open-label trial evaluated the treatment responses of adults with ...

Bloomreach, the agentic platform for personalization, today introduced Personalized Media in-Grid, a new capability that turns static product grids into intelligent storytelling surfaces ? powered by ...

In many modern sciences, data often exist on curved geometric spaces rather than flat planes, posing challenges for traditional statistical tools. These curved spaces are called Riemannian manifolds.